An open label, randomised healthy volunteer study to assess the single dose safety and pharmacokinetics of three modified release dosage forms of firategrast
Phase of Trial: Phase I
Latest Information Update: 23 Jun 2017
At a glance
- Drugs Firategrast (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 25 Aug 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health NCT01424462).
- 10 Aug 2010 New trial record.